JP2006232855A - 抗真菌組成物 - Google Patents
抗真菌組成物 Download PDFInfo
- Publication number
- JP2006232855A JP2006232855A JP2006156419A JP2006156419A JP2006232855A JP 2006232855 A JP2006232855 A JP 2006232855A JP 2006156419 A JP2006156419 A JP 2006156419A JP 2006156419 A JP2006156419 A JP 2006156419A JP 2006232855 A JP2006232855 A JP 2006232855A
- Authority
- JP
- Japan
- Prior art keywords
- antifungal
- hydrochloride
- antifungal composition
- magnesium
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012871 anti-fungal composition Substances 0.000 title claims abstract description 24
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 30
- 239000003429 antifungal agent Substances 0.000 claims abstract description 28
- -1 fatty acid ester Chemical class 0.000 claims abstract description 21
- 239000002904 solvent Substances 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 17
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 14
- 239000000194 fatty acid Substances 0.000 claims abstract description 14
- 229930195729 fatty acid Natural products 0.000 claims abstract description 14
- 230000001139 anti-pruritic effect Effects 0.000 claims abstract description 13
- 239000003908 antipruritic agent Substances 0.000 claims abstract description 11
- 229960002962 butenafine Drugs 0.000 claims abstract description 5
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 16
- 239000000443 aerosol Substances 0.000 claims description 12
- 239000011787 zinc oxide Substances 0.000 claims description 10
- 235000014692 zinc oxide Nutrition 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
- 239000000454 talc Substances 0.000 claims description 8
- 229910052623 talc Inorganic materials 0.000 claims description 8
- 239000003380 propellant Substances 0.000 claims description 7
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229960004194 lidocaine Drugs 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 4
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229960003338 crotamiton Drugs 0.000 claims description 3
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 claims description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 claims description 2
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 229920002675 Polyoxyl Polymers 0.000 claims description 2
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 229960005274 benzocaine Drugs 0.000 claims description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 2
- 229940105847 calamine Drugs 0.000 claims description 2
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960003291 chlorphenamine Drugs 0.000 claims description 2
- 229960001747 cinchocaine Drugs 0.000 claims description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 2
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 229940045574 dibucaine hydrochloride Drugs 0.000 claims description 2
- 229940031578 diisopropyl adipate Drugs 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- 229960002392 diphenylpyraline hydrochloride Drugs 0.000 claims description 2
- LPRLDRXGWKXRMQ-UHFFFAOYSA-N diphenylpyraline hydrochloride Chemical compound [Cl-].C1C[NH+](C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 LPRLDRXGWKXRMQ-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- 229910052864 hemimorphite Inorganic materials 0.000 claims description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims description 2
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000391 magnesium silicate Substances 0.000 claims description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 2
- 235000019792 magnesium silicate Nutrition 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 239000010445 mica Substances 0.000 claims description 2
- 229910052618 mica group Inorganic materials 0.000 claims description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 claims description 2
- QWPNJOHZHSJFIY-UHFFFAOYSA-N octyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCCCCCC QWPNJOHZHSJFIY-UHFFFAOYSA-N 0.000 claims description 2
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 claims description 2
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229960004919 procaine Drugs 0.000 claims description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960001309 procaine hydrochloride Drugs 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000001593 sorbitan monooleate Substances 0.000 claims description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 2
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- HZZOEADXZLYIHG-UHFFFAOYSA-N magnesiomagnesium Chemical compound [Mg][Mg] HZZOEADXZLYIHG-UHFFFAOYSA-N 0.000 claims 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 28
- 201000009862 superficial mycosis Diseases 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 230000001476 alcoholic effect Effects 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 13
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 12
- SUMAWDZJEIQACJ-UHFFFAOYSA-N 2-methylpyridine-4-carbaldehyde Chemical compound CC1=CC(C=O)=CC=N1 SUMAWDZJEIQACJ-UHFFFAOYSA-N 0.000 description 9
- 230000000843 anti-fungal effect Effects 0.000 description 9
- 229960003273 butenafine hydrochloride Drugs 0.000 description 9
- 238000013329 compounding Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 6
- 102000011782 Keratins Human genes 0.000 description 6
- 108010076876 Keratins Proteins 0.000 description 6
- 229960003720 enoxolone Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 208000002474 Tinea Diseases 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000013844 butane Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- FLIBKIRHXYPCJV-UHFFFAOYSA-N ethanol;propan-2-yl tetradecanoate Chemical compound CCO.CCCCCCCCCCCCCC(=O)OC(C)C FLIBKIRHXYPCJV-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical class CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- QJBZDBLBQWFTPZ-UHFFFAOYSA-N pyrrolnitrin Chemical compound [O-][N+](=O)C1=C(Cl)C=CC=C1C1=CNC=C1Cl QJBZDBLBQWFTPZ-UHFFFAOYSA-N 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZRTQSJFIDWNVJW-WYMLVPIESA-N Lanoconazole Chemical compound ClC1=CC=CC=C1C(CS\1)SC/1=C(\C#N)N1C=NC=C1 ZRTQSJFIDWNVJW-WYMLVPIESA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- MQHLMHIZUIDKOO-AYHJJNSGSA-N amorolfine Chemical compound C1=CC(C(C)(C)CC)=CC=C1CC(C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-AYHJJNSGSA-N 0.000 description 1
- 229960005279 amorolfine hydrochloride Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- RTSZUSOHOIFYSY-UHFFFAOYSA-N diphenhydramine salicylate Chemical compound OC1=CC=CC=C1C([O-])=O.C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 RTSZUSOHOIFYSY-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229950010163 lanoconazole Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229950010757 neticonazole Drugs 0.000 description 1
- VWOIKFDZQQLJBJ-DTQAZKPQSA-N neticonazole Chemical compound CCCCCOC1=CC=CC=C1\C(=C/SC)N1C=NC=C1 VWOIKFDZQQLJBJ-DTQAZKPQSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229960002132 pyrrolnitrin Drugs 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】 ベンジルアミン系抗真菌剤に脂肪酸エステル、粉末成分、アルコール系溶剤および鎮痒成分を配合してなる抗真菌組成物である。好ましいベンジルアミン系抗真菌剤は、ブテナフィンおよびそれらの塩からなる群より選ばれる少なくとも1つである。ベンジルアミン系抗真菌剤の配合量は組成物中0.05〜5重量%である。
【選択図】 なし
Description
塩酸ブテナフィン 1g
リドカイン 2g
グリチルリチン酸二カリウム 1g
塩酸クロルヘキシジン 0.2g
酸化亜鉛 10g
ステアリン酸マグネシウム 0.5g
タルク 55.3g
ミリスチン酸イソプロピル 15g
イソプロピルアルコール 15g
全量 100g
塩酸ブテナフィン 1g
リドカイン 2.5g
グリチルレチン酸 1g
酸化亜鉛 10g
タルク 10g
ミリスチン酸イソプロピル 5g
エタノール 70.5g
全量 100g
塩酸ブテナフィン 1g
塩酸ジフェンヒドラミン 2g
グリチルレチン酸 1g
塩酸クロルヘキシジン 1g
酸化亜鉛 10g
タルク 10g
ミリスチン酸イソプロピル 30g
エタノール 45g
全量 100g
塩酸ブテナフィン 1g
リドカイン 2.5g
グリチルレチン酸 1g
塩酸クロルヘキシジン 1g
酸化亜鉛 10g
タルク 30g
ミリスチン酸イソプロピル 18.5g
エタノール 36g
全量 100g
塩酸ブテナフィン 1g
リドカイン 2.5g
グリチルレチン酸 1g
酸化亜鉛 10g
タルク 20g
ミリスチン酸イソプロピル 20g
エタノール 45.5g
全量 100g
塩酸ブテナフィン 1g
塩酸ジフェンヒドラミン 2g
グリチルレチン酸 1g
イソプロピルメチルフェノール 3g
酸化亜鉛 10g
タルク 17g
ミリスチン酸イソプロピル 20g
エタノール 46g
全量 100g
1)使用感試験
表1に示す配合割合の実施例1、比較例1〜4の抗真菌組成物サンプルについて下記の方法で使用感を評価した。すなわち、7名のパネラーの足指間の同じ箇所に試験サンプルを塗布し、塗布時の塗布し易さ、乾き易さ、塗布後8時間の塗布部分(足指間)のサラサラ感、および、それらを総合的にみた総合的使用感について、下記の評価基準でスコアを付けた。
良い:5点
やや良い:4点
どちらでもない:3点
やや悪い:2点
悪い:1点
最高スコアは、全評価項目において被験者全員が「良い:5点」と評価した場合のスコアであり、5点×7名×4項目=140点である。
表1に示す配合割合の実施例1、比較例1〜4の抗真菌組成物サンプルについて、下記の方法でマウスにおける鎮痒効果を評価した。
表1に示す配合割合の実施例1、比較例1〜4の抗真菌組成物サンプルについて、下記の方法でモルモットにおける抗真菌効果を評価した。
Slc:Haryley系モルモット 6週齢 (雄)
(試験サンプルあたり6匹使用)
<使用菌株>
Trichophyton mentagrophytes
まず、この菌をサブロー寒天斜面培地(栄研化学社製)上で27℃、14日間培養し、次いで滅菌生理食塩水を加えて菌を遊離させ、滅菌済みフィルター(100μm、セルス トレイナー:FALCON社製)で濾過し、2×107/mlの菌液を調製した。
モルモットは、1週間飼育し、馴化してから試験に供した。まず、モルモットをペントバルビタールナトリウム麻酔(50mg/ml/kg;ネンブタール注射液(大日本製薬社製)を腹くう内投与)下で、背部を抜毛した。こうして、モルモット1匹に対し、6箇所、被試験物質が交差しないように2cm間隔で2cm×2cmの被験部位を設けた。次いで、抜毛部位(被験部位)を2cm角布粘着テープで3回ストリッピングし、皮膚角質層上部を除去した。酒精綿で皮膚表面を消毒した後、1部位あたり0.1mlの菌液を接種した。接種後、検体動物を湿度60〜68%、温度27℃の条件下で飼育し、接種後5日目から8日間、連続して1日1回、試験サンプルを0.3g塗布し、20回手指で刷り込んだ。感染部位の病変度を1日1回観察し、下記基準に従いスコアを付けた。
局所病変が全く認められない状態:0
少数個の小さな紅斑または紅斑性丘疹が島状に散剤して認められる状態、または病変が軽快し新しい被毛が発育してきた状態:1
紅斑が感染部位に広がり、表皮の剥離を伴う状態:2
部分的に強い発赤、腫張などの炎症反応がみられ、豊富に鱗屑が生じる状態:3
肥厚したカ皮の形成、出血性びらんまたは潰瘍が見られる状態:4
試験開始から13日目(薬剤塗布開始から8日目)の被験部位6箇所のスコアの平均値より、試験サンプルの抗真菌活性の有効性を評価した。
Claims (8)
- ベンジルアミン系坑真菌剤に脂肪酸エステル、粉末成分、アルコール系溶剤および鎮痒成分を配合してなる抗真菌組成物。
- ベンジルアミン系抗真菌剤がブテナフィンおよびそれらの塩からなる群より選ばれる少なくとも1つである請求項1記載の抗真菌組成物。
- 脂肪酸エステルがミリスチン酸イソプロピル、ミリスチン酸オクチル、ステアリン酸ブチル、オレイン酸エチル、オレイン酸オレイル、アジピン酸ジイソプロピル、グリセリン脂肪酸エステル、ステアリン酸ポリオキシル40、同45、同55、セバシン酸ジエチル、ソルビタン脂肪酸エステル、パルミチン酸イソプロピル、モノオレイン酸グリセリンおよびモノオレイン酸ソルビタンからなる群より選ばれる少なくとも1つである請求項1または2記載の抗真菌組成物。
- 粉末成分がタルク、酸化亜鉛、酸化チタン、ステアリン酸マグネシウム、ステアリン酸亜鉛、酸化マグネシウム、炭酸マグネシウム、カラミン、メタケイ酸アルミン酸マグネシウム、無水ケイ酸、ケイ酸マグネシウム、カオリン、アエロジル、マイカ、トウモロコシデンプンからなる群より選ばれる少なくとも1つである請求項1〜3のいずれかに記載の抗真菌組成物。
- 鎮痒成分がリドカイン、ジブカイン、プロカイン、塩酸ジブカイン、塩酸リドカイン、塩酸プロカイン、アミノ安息香酸エチル、オキシポリエントキシドデカン、塩酸ジフェニルピラリン、塩酸ジフェンヒドラミン、クロルフェニラミン、サリチル酸ジフェンヒドミン、クロタミトンからなる群より選ばれる少なくとも1つである請求項1〜4のいずれかに記載の抗真菌組成物。
- アルコール系溶剤がメタノール、エタノール、プロパノール、ブタノール、ベンジルアルコール、グリセリン、エチレングリコールおよびこれらの構造異性体からなる群より選ばれる少なくとも1つである請求項1〜5のいずれかに記載の抗真菌組成物。
- 抗真菌剤を0.05〜5重量%、脂肪族エステルを5〜31.96重量%、粉末成分を20〜50重量%、アルコール系溶剤を29.94〜74.9重量%、および鎮痒成分を0.05〜10重量%含む請求項1〜6のいずれかに記載の抗真菌組成物。
- 請求項1〜7のいずれかに記載の抗真菌組成物5〜30重量%と、噴射剤95〜70重量%とからなるエアゾール剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006156419A JP5097363B2 (ja) | 2006-06-05 | 2006-06-05 | 抗真菌組成物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006156419A JP5097363B2 (ja) | 2006-06-05 | 2006-06-05 | 抗真菌組成物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003341723A Division JP2005104917A (ja) | 2003-09-30 | 2003-09-30 | 抗真菌組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006232855A true JP2006232855A (ja) | 2006-09-07 |
JP5097363B2 JP5097363B2 (ja) | 2012-12-12 |
Family
ID=37040879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006156419A Expired - Lifetime JP5097363B2 (ja) | 2006-06-05 | 2006-06-05 | 抗真菌組成物 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5097363B2 (ja) |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60161921A (ja) | 1984-01-18 | 1985-08-23 | ジヨンソン・アンド・ジヨンソン・ベイビー・プロダクツ・カンパニー | スキンケア組成物 |
JPS60215092A (ja) * | 1984-04-09 | 1985-10-28 | Kao Corp | 人体塗布用粉末エアゾ−ル組成物 |
JPH02290810A (ja) * | 1989-04-28 | 1990-11-30 | Hisamitsu Pharmaceut Co Inc | エアゾール製剤 |
JPH05246843A (ja) | 1990-09-26 | 1993-09-24 | L'oreal Sa | 抗真菌剤組成物 |
JPH06211651A (ja) * | 1993-01-12 | 1994-08-02 | Hisamitsu Pharmaceut Co Inc | 爪白癬治療用組成物 |
JPH07233088A (ja) | 1993-12-27 | 1995-09-05 | Takeda Chem Ind Ltd | 局所外用剤 |
JPH0812964A (ja) * | 1994-07-01 | 1996-01-16 | Kobayashi Pharmaceut Co Ltd | 粉末エアゾール組成物 |
JPH08291050A (ja) | 1995-02-22 | 1996-11-05 | Hisamitsu Pharmaceut Co Inc | エアゾール組成物及びエアゾール型外用製剤 |
JPH11279053A (ja) | 1998-03-30 | 1999-10-12 | Kobayashi Pharmaceut Co Ltd | 掻痒性皮膚疾患用噴霧剤 |
JP2000229845A (ja) * | 1998-12-10 | 2000-08-22 | Taisho Pharmaceut Co Ltd | 抗真菌剤含有粉末エアゾール製剤 |
WO2000062776A1 (fr) * | 1999-04-16 | 2000-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Compositions antifongiques |
JP2001181182A (ja) * | 1999-12-22 | 2001-07-03 | Takeda Chem Ind Ltd | 抗真菌性液体外用組成物 |
JP2001335083A (ja) | 2000-05-26 | 2001-12-04 | Daizo:Kk | エアゾール製品 |
JP2002284702A (ja) * | 2001-01-19 | 2002-10-03 | Teika Seiyaku Kk | 外用抗真菌製剤 |
JP2002363101A (ja) * | 2001-04-03 | 2002-12-18 | Taisho Pharmaceut Co Ltd | 外用剤 |
JP2003252798A (ja) * | 2002-02-28 | 2003-09-10 | Shiseido Co Ltd | 抗菌ゲル製剤 |
JP2005104916A (ja) | 2003-09-30 | 2005-04-21 | Kobayashi Pharmaceut Co Ltd | 抗真菌組成物 |
JP2005104918A (ja) | 2003-09-30 | 2005-04-21 | Kobayashi Pharmaceut Co Ltd | 抗真菌組成物 |
-
2006
- 2006-06-05 JP JP2006156419A patent/JP5097363B2/ja not_active Expired - Lifetime
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60161921A (ja) | 1984-01-18 | 1985-08-23 | ジヨンソン・アンド・ジヨンソン・ベイビー・プロダクツ・カンパニー | スキンケア組成物 |
JPS60215092A (ja) * | 1984-04-09 | 1985-10-28 | Kao Corp | 人体塗布用粉末エアゾ−ル組成物 |
JPH02290810A (ja) * | 1989-04-28 | 1990-11-30 | Hisamitsu Pharmaceut Co Inc | エアゾール製剤 |
JPH05246843A (ja) | 1990-09-26 | 1993-09-24 | L'oreal Sa | 抗真菌剤組成物 |
JPH06211651A (ja) * | 1993-01-12 | 1994-08-02 | Hisamitsu Pharmaceut Co Inc | 爪白癬治療用組成物 |
JPH07233088A (ja) | 1993-12-27 | 1995-09-05 | Takeda Chem Ind Ltd | 局所外用剤 |
JPH0812964A (ja) * | 1994-07-01 | 1996-01-16 | Kobayashi Pharmaceut Co Ltd | 粉末エアゾール組成物 |
JPH08291050A (ja) | 1995-02-22 | 1996-11-05 | Hisamitsu Pharmaceut Co Inc | エアゾール組成物及びエアゾール型外用製剤 |
JPH11279053A (ja) | 1998-03-30 | 1999-10-12 | Kobayashi Pharmaceut Co Ltd | 掻痒性皮膚疾患用噴霧剤 |
JP2000229845A (ja) * | 1998-12-10 | 2000-08-22 | Taisho Pharmaceut Co Ltd | 抗真菌剤含有粉末エアゾール製剤 |
WO2000062776A1 (fr) * | 1999-04-16 | 2000-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Compositions antifongiques |
JP2001181182A (ja) * | 1999-12-22 | 2001-07-03 | Takeda Chem Ind Ltd | 抗真菌性液体外用組成物 |
JP2001335083A (ja) | 2000-05-26 | 2001-12-04 | Daizo:Kk | エアゾール製品 |
JP2002284702A (ja) * | 2001-01-19 | 2002-10-03 | Teika Seiyaku Kk | 外用抗真菌製剤 |
JP2002363101A (ja) * | 2001-04-03 | 2002-12-18 | Taisho Pharmaceut Co Ltd | 外用剤 |
JP2003252798A (ja) * | 2002-02-28 | 2003-09-10 | Shiseido Co Ltd | 抗菌ゲル製剤 |
JP2005104916A (ja) | 2003-09-30 | 2005-04-21 | Kobayashi Pharmaceut Co Ltd | 抗真菌組成物 |
JP2005104918A (ja) | 2003-09-30 | 2005-04-21 | Kobayashi Pharmaceut Co Ltd | 抗真菌組成物 |
Non-Patent Citations (7)
Title |
---|
JPN3013000003; 調剤と情報 V9,N6, 200306, 株式会社じほう |
JPN3013000004; メンタックスクリーム , 200806, 科研製薬株式会社 |
JPN3013000005; フロリードDクリーム , 200612, 持田製薬株式会社 |
JPN3013000006; エンペシドクリーム , 199512, バイエル薬品株式会社 |
JPN3013000007; 薬理と治療 V10,N7, 19820720, P89-103, ライフ・サイエンス出版株式会社 |
JPN3013000008; ANTIMICROBIAL AGENTS AND CHEMOTHERAPY及び訳文 V34,N11, 199011, P2250-2253 |
JPN3013000009; ANTIMICROBIAL AGENTS AND CHEMOTHERAPY及び訳文 V34,N11, 199011, P2254-2255 |
Also Published As
Publication number | Publication date |
---|---|
JP5097363B2 (ja) | 2012-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2532133T3 (es) | Composiciones y métodos para el tratamiento de enfermedades de la uña | |
JP4828563B2 (ja) | 水虫治療用外用剤 | |
US9861698B2 (en) | Compositions and methods for treating diseases of the nail | |
CA2673976C (en) | Gel composition for treating mycosis | |
KR20060003868A (ko) | 항진균성 네일 코트 및 사용 방법 | |
WO2014140925A2 (en) | Topical compositions and methods of treatment of topical disorders | |
EP1931309B1 (en) | Antifungal composition | |
JPH10152433A (ja) | 被膜形成性抗真菌剤組成物 | |
JP2006232856A (ja) | 抗真菌組成物 | |
JP5033381B2 (ja) | 外用医薬組成物 | |
WO2005099764A1 (ja) | 抗真菌性外用組成物 | |
WO2011061155A1 (en) | Antifungal formulations and their use | |
JP2005104917A (ja) | 抗真菌組成物 | |
JP5097363B2 (ja) | 抗真菌組成物 | |
JP2005104916A (ja) | 抗真菌組成物 | |
JP2005104918A (ja) | 抗真菌組成物 | |
JP2006232854A (ja) | 抗真菌組成物 | |
JP6512599B2 (ja) | 外用医薬組成物 | |
CA2495923A1 (en) | Methods for treating fungal infections | |
US11154542B2 (en) | Nail lacquer composition containing ciclopirox | |
JP7475468B2 (ja) | 皮膜形成エアゾール組成物及びエアゾール型皮膜形成外用製剤 | |
JP5460766B2 (ja) | 外用医薬組成物 | |
BRPI0709834B1 (pt) | composições antioxidantes para redução de odor em composições lubrificantes que aquecem | |
MX2008004132A (en) | Antifungal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100316 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100316 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100427 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101013 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101228 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20110204 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120924 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5097363 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150928 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150928 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |